Latest Breaking News On - Translationalsession date - Page 1 : comparemela.com

CellCentric presents early clinical data at ASH: inobrodib (CCS1477), first in class p300/CBP bromodomain inhibitor treating relapsed refractory multiple myeloma

CellCentric presents early clinical data at ASH: inobrodib (CCS1477), first in class p300/CBP bromodomain inhibitor treating relapsed refractory multiple myeloma
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomPrnewswire cellcentricTim somervaillePaul richardsonAzim suraniLeif bergsagelDepartment of internal medicineUniversity of manchesterGurdon instituteHarvard medical schoolErnestn morial convention centerAmerican society of haematologyTakeda pharmaceuticalsUniversity of cambridgeClinical research

CellCentric to present inobrodib Phase I multiple myeloma efficacy and safety data at the American Society of Haematology

CellCentric to present inobrodib Phase I multiple myeloma efficacy and safety data at the American Society of Haematology
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesAndrew hughesPrnewswire cellcentricTim somervailleAzim suraniUniversity of cambridgeTakeda pharmaceuticalsUniversity of manchesterGurdon instituteErnestn morial convention centerAmerican society of haematologyNew orleansChief investigatorProfessor tim somervailleAmerican society